Related Experiment Video
Updated: Dec 23, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Complete response after ceritinib treatment in non-small cell lung cancer in an elderly patient
Nilay Sengul Samanci1, Emir Celik1, Burak Akovalı2
1Medical Oncology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey.
Introduction:
Ceritinib is a selective second-generation ALK inhibitor that is highly sensitive to echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) molecule.
Case Report:
In this paper, we report a 68-year-old female that was diagnosed with stage 4 ALK-positive non-small cell lung cancer (NSCLC).Management and outcome: She was treated with crizotinib first-line, cisplatin and gemcitabine as second-line. And for third-line, ceritinib was started. She had complete response over 3.5 years under ceritinib treatment. And she is still receiving ceritinib with no adverse event.
Discussion:
Cases achieving complete response with ceritinib treatment are rare. In this paper, we aimed to emphasize the complete response in stage 4 NSCLC in an elderly patient.
Related Concept Videos
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
Drug Dosing: Geriatric Patients
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Pharmacodynamics in Geriatric Patients: Effects of Age
